SCHEMBL26640784

SCHEMBL26640784

CS(=O)(=O)Cc1ccc(Nc2ncc3c(n2)CNCC3)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.45
CDK5 Q00535 7/20 0.40
CDK5R1 Q15078 7/20 0.40
CDK2 P24941 5/20 0.40
CCNA2 P20248 4/20 0.40
HTR2C P28335 1/20 0.39
GRM5 P41594 2/20 0.38
CDK1 P06493 3/20 0.37
CCNB1 P14635 3/20 0.37
CCNT1 O60563 2/20 0.37
CCNE1 P24864 2/20 0.37
CDK9 P50750 2/20 0.37
CCND3 P30281 1/20 0.37
FLT3 P36888 1/20 0.37
CDK6 Q00534 1/20 0.37
CAMK2D Q13557 1/20 0.37
WEE1 P30291 3/20 0.36
BTK Q06187 1/20 0.36
MAOB P27338 1/20 0.35
IKBKB O14920 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26640174 0.87 CDK5 (0.47) MAP4K1CDK5CDK5R1CDK2CCNA2
SCHEMBL26640773 0.87 HTR2C (0.37) MAP4K1CDK5CDK5R1CDK2CCNA2
SCHEMBL26640504 0.85 CDK5 (0.40) MAP4K1CDK5CDK5R1CDK2CCNA2
SCHEMBL26640884 0.82 CDK5 (0.41) CDK5CDK5R1CDK2CCNA2CDK1
SCHEMBL30648740 0.82 CDK5 (0.54) CDK5CDK5R1CDK2CCNA2GRM5
SCHEMBL26640576 0.82 CDK5 (0.54) CDK5CDK5R1CDK2CCNA2GRM5
SCHEMBL26640697 0.82 CDK5 (0.49) CDK5CDK5R1CDK2CCNA2HTR2C
SCHEMBL30648748 0.82 PTK2 (0.40) CDK5CDK5R1CDK2CCNA2GRM5
SCHEMBL26640969 0.82 PTK2 (0.40) CDK5CDK5R1CDK2CCNA2GRM5
SCHEMBL26640551 0.81 AXL (0.37) MAP4K1CDK5CDK5R1CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 MAP4K1 50/4885CDK5 389/4885CDK5R1 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.